Inflammation  >>  pioglitazone  >>  Phase 3
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pioglitazone / Generic mfg.
ACTRN12608000534381: Double blind, randomised, comparative, multicentre, parallel-group study design to evaluate the effects of Pioglitazone on cardiovascular risk markers in type 2 diabetes mellitus

Completed
3
100
 
Takeda Italia Farmaceutici S.p.A., Takeda Italia Farmaceutici S.p.A.
Type 2 diabetes
 
 
PEGLIST C, NCT00927290 / 2008-006225-14: Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance

Terminated
3
40
Europe
Pioglitazone, Placebo
French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis C, Insulin Resistance
07/12
07/12
2012-004100-35: clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, on cardiovascular risk factors and on risk factors for the development of type 2 diabetes Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de riesgo cardiovascular y de desarrollo de diabetes tipo 2.

Ongoing
3
40
Europe
Metformina, espironolactona, Clorhidrato de pioglitazona, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO
Fundació per la Recerca i la Docència Sant Joan de Déu, Ministerio de Sanidad y Política Social
Ovarian hyperandrogenism hiperandrogenismo ovárico
 
 
2015-005092-24: Clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, treatment markers of pronostic and effectiveness and the development of type 2 diabetes. Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de evolución y efectividad del tratamiento y de desarrollo de diabetes tipo 2.

Ongoing
3
40
Europe
Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO, Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO
FUNDACIÓ SANT JOAN DE DÉU, Ministerio de Sanidad y Política Social
ovarian hyperandrogenism with hyperinsulinaemia hiperandrogenismo ovárico con hiperinsulinismo
 
 
NCT00153166: ARREST PAD (Peripheral Arterial Disease)

Completed
2/3
76
US
atorvastatin and pioglitazone, atorvastatin: lipitor, pioglitazone: actos, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)
Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
11/10
12/11
NCT01184144: Endometriosis: Immunomodulation

Withdrawn
2/3
0
US
Pioglitazone, Actos
University of Wisconsin, Madison
Endometriosis
05/12
05/12

Download Options